What is Allergy Options?
Founded in 2012, Allergy Options operates at the intersection of clinical diagnostics and primary care integration. The company addresses the critical need for accessible allergy testing and immunotherapy, particularly in regions experiencing rising rates of airborne and mold-related sensitivities. By co-locating its services within existing primary care practices, Allergy Options facilitates a seamless patient experience that prioritizes thorough medical history and immediate therapeutic intervention. This model not only empowers primary care physicians to offer comprehensive allergy care but also provides patients with a convenient alternative to traditional, fragmented specialist referrals. The company's market position is defined by its commitment to improving long-term quality of life through effective, sustainable treatment options rather than temporary symptom management.
How much funding has Allergy Options raised?
Allergy Options has raised a total of $32K across 1 funding round:
Debt
$32K
Debt (2021): $32K with participation from PPP
Key Investors in Allergy Options
PPP
Public-Private Partnership
What's next for Allergy Options?
Looking ahead, the company is well-positioned to leverage its recent capital to expand its clinical network and refine its diagnostic infrastructure. The strategic focus will likely center on deepening partnerships with primary care providers to standardize allergy treatment protocols across high-demand regions. As the organization scales, it will continue to prioritize the integration of data-driven insights into its clinical workflows, ensuring that patient care remains both personalized and highly effective. By maintaining its focus on physician-led, on-site testing, Allergy Options is set to capture a larger share of the allergy management market, ultimately setting a new standard for how chronic respiratory and environmental sensitivities are addressed within the broader healthcare ecosystem.
See full Allergy Options company page
